MetLife Investment Management LLC Has $10.92 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

MetLife Investment Management LLC decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the third quarter, HoldingsChannel reports. The firm owned 46,082 shares of the medical research company’s stock after selling 3,423 shares during the period. MetLife Investment Management LLC’s holdings in IQVIA were worth $10,920,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. CreativeOne Wealth LLC increased its position in shares of IQVIA by 21.2% in the third quarter. CreativeOne Wealth LLC now owns 3,167 shares of the medical research company’s stock worth $750,000 after acquiring an additional 553 shares in the last quarter. Blueshift Asset Management LLC grew its position in IQVIA by 53.2% during the 3rd quarter. Blueshift Asset Management LLC now owns 3,716 shares of the medical research company’s stock worth $881,000 after purchasing an additional 1,290 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in shares of IQVIA by 144.0% in the third quarter. Glenmede Trust Co. NA now owns 306,511 shares of the medical research company’s stock valued at $72,634,000 after purchasing an additional 180,890 shares in the last quarter. Townsquare Capital LLC grew its holdings in shares of IQVIA by 5.8% during the third quarter. Townsquare Capital LLC now owns 12,214 shares of the medical research company’s stock valued at $2,894,000 after buying an additional 666 shares in the last quarter. Finally, Baldwin Investment Management LLC raised its position in IQVIA by 8.6% during the third quarter. Baldwin Investment Management LLC now owns 3,548 shares of the medical research company’s stock valued at $841,000 after buying an additional 280 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IQV. Morgan Stanley dropped their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. The Goldman Sachs Group dropped their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Price Performance

NYSE IQV opened at $201.43 on Friday. The stock has a 50-day simple moving average of $219.50 and a 200 day simple moving average of $226.40. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock has a market capitalization of $36.56 billion, a PE ratio of 26.43, a P/E/G ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.